Operative approach and case volume are associated with negative resection margins for adrenocortical carcinoma.

Adrenocortical carcinoma Laparoscopic surgery Margins Minimally invasive surgery National Cancer Database Robotic surgery

Journal

Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653

Informations de publication

Date de publication:
12 2022
Historique:
received: 03 09 2021
accepted: 21 02 2022
pubmed: 6 3 2022
medline: 16 11 2022
entrez: 5 3 2022
Statut: ppublish

Résumé

Surgical resection with negative margins is the treatment of choice for adrenocortical carcinoma (ACC). This study was undertaken to determine factors associated with negative resection margins. National Cancer Database was queried from 2010 to 2016 to identify patients with AJCC/ENSAT Stage I-III ACC who underwent adrenalectomy. Patient, tumor, facility, and operative characteristics were compared by margin status (positive-PM or negative-NM) and operative approach (open-OA, laparoscopic-LA, or robotic-RA). Multivariable logistic regression was used to identify factors associated with PM. Eight hundred and eighty-one patients were identified, of which 18.4% had PM and 81.6% had NM. Patients with advanced pathologic T stage and pathologic N1 stage were more likely to have PM (vs. NM) (T3, 49.7% vs. 24.8%, p < 0.01; T4, 26.2% vs. 10.0%, p < 0.01; N1, 6.7% vs. 3.5%, p < 0.01). Patients undergoing OA (vs. LA and RA) were more likely to have advanced clinical T stage (T4, 16.6% vs. 5.7% vs. 7.8%, p < 0.01) and larger tumors (> 6 cm, 84.6% vs. 64.1% vs. 62.3%, p < 0.01). High-volume centers (≥ 5 cases) were more likely to utilize OA. Patients undergoing LA (vs. RA) were more likely to require conversion to open (20.3% vs. 7.8%, p = 0.011). On multivariable analysis, factors associated with higher odds of PM included T3 disease (OR 7.02, 95% CI 2.66-18.55), T4 disease (OR 10.22, 95% CI 3.66-28.53), and LA (OR 1.99, 95% CI 1.28-3.09). High-volume centers were associated with lower odds of PM (OR 0.67, 95% CI 0.45-0.98). There was no significant difference in margin status between OA and RA (OR 1.44, 95% CI 0.71-2.90). Centers with higher ACC case volumes have lower odds of PM and utilize OA more often. LA is associated with higher odds of PM, whereas RA is not. These factors should be considered when planning the operative approach for ACC.

Sections du résumé

BACKGROUND
Surgical resection with negative margins is the treatment of choice for adrenocortical carcinoma (ACC). This study was undertaken to determine factors associated with negative resection margins.
METHODS
National Cancer Database was queried from 2010 to 2016 to identify patients with AJCC/ENSAT Stage I-III ACC who underwent adrenalectomy. Patient, tumor, facility, and operative characteristics were compared by margin status (positive-PM or negative-NM) and operative approach (open-OA, laparoscopic-LA, or robotic-RA). Multivariable logistic regression was used to identify factors associated with PM.
RESULTS
Eight hundred and eighty-one patients were identified, of which 18.4% had PM and 81.6% had NM. Patients with advanced pathologic T stage and pathologic N1 stage were more likely to have PM (vs. NM) (T3, 49.7% vs. 24.8%, p < 0.01; T4, 26.2% vs. 10.0%, p < 0.01; N1, 6.7% vs. 3.5%, p < 0.01). Patients undergoing OA (vs. LA and RA) were more likely to have advanced clinical T stage (T4, 16.6% vs. 5.7% vs. 7.8%, p < 0.01) and larger tumors (> 6 cm, 84.6% vs. 64.1% vs. 62.3%, p < 0.01). High-volume centers (≥ 5 cases) were more likely to utilize OA. Patients undergoing LA (vs. RA) were more likely to require conversion to open (20.3% vs. 7.8%, p = 0.011). On multivariable analysis, factors associated with higher odds of PM included T3 disease (OR 7.02, 95% CI 2.66-18.55), T4 disease (OR 10.22, 95% CI 3.66-28.53), and LA (OR 1.99, 95% CI 1.28-3.09). High-volume centers were associated with lower odds of PM (OR 0.67, 95% CI 0.45-0.98). There was no significant difference in margin status between OA and RA (OR 1.44, 95% CI 0.71-2.90).
CONCLUSION
Centers with higher ACC case volumes have lower odds of PM and utilize OA more often. LA is associated with higher odds of PM, whereas RA is not. These factors should be considered when planning the operative approach for ACC.

Identifiants

pubmed: 35246741
doi: 10.1007/s00464-022-09167-0
pii: 10.1007/s00464-022-09167-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9288-9296

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, Naing A, Sircar K, Wood CG, Pagliaro L, Jimenez C, Vassilopoulou-Sellin R, Habra MA (2013) Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol 169:891–899
doi: 10.1530/EJE-13-0519 pubmed: 24086089 pmcid: 4441210
Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A (2006) Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg 30:872–878
doi: 10.1007/s00268-005-0329-x pubmed: 16680602
Schulick RD, Brennan MF (1999) Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 6:719–726
doi: 10.1007/s10434-999-0719-7 pubmed: 10622498
Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25:891–897
doi: 10.1007/s00268-001-0047-y pubmed: 11572030
Tella SH, Kommalapati A, Yaturu S, Kebebew E (2018) Predictors of survival in adrenocortical carcinoma: an analysis from the National Cancer Database. J Clin Endocrinol Metab 103:3566–3573
doi: 10.1210/jc.2018-00918 pubmed: 29982685
Gonzalez RJ, Shapiro S, Sarlis N, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE (2005) Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. J Surgery 138:1078–1085
Leboulleux S, Deandreis D, Al Ghuzlan A, Aupérin A, Goéré D, Dromain C, Elias D, Caillou B, Travagli JP, De Baere T, Lumbroso J, Young J, Schlumberger M, Baudin E (2010) Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol 162:1147–1153
doi: 10.1530/EJE-09-1096 pubmed: 20348273
Miller BS, Ammori JB, Gauger PG, Broome JT, Hammer GD, Doherty GM (2010) Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg 34:1380–1385
doi: 10.1007/s00268-010-0532-2 pubmed: 20372905
National Comprehensive Cancer Network Neuroendocrine and Adrenal Tumors (Version 2.2020).
Gratian L, Pura J, Dinan M, Reed S, Scheri R, Roman S, Sosa JA (2014) Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States. Ann Surg Oncol 21:3509–3514
doi: 10.1245/s10434-014-3931-z pubmed: 25069860 pmcid: 4515350
Park HS, Roman SA, Sosa JA (2009) Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty? Arch Surg 144:1060–1067
doi: 10.1001/archsurg.2009.191 pubmed: 19917944
Margonis GA, Kim Y, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Poultsides GA, Pawlik TM (2016) Adrenocortical carcinoma: impact of surgical margin status on long-term outcomes. Ann Surg Oncol 23:134–141
doi: 10.1245/s10434-015-4803-x pubmed: 26286195
Brunaud L, Ayav A, Zarnegar R, Rouers A, Klein M, Boissel P, Bresler L (2008) Prospective evaluation of 100 robotic-assisted unilateral adrenalectomies. Surgery 144:995–1001
doi: 10.1016/j.surg.2008.08.032 pubmed: 19041009
Agcaoglu O, Aliyev S, Karabulut K, Siperstein A, Berber E (2012) Robotic vs laparoscopic posterior retroperitoneal adrenalectomy. Arch Surg 147:272–275
doi: 10.1001/archsurg.2011.2040 pubmed: 22430911
Hupe MC, Imkamp F, Merseburger AS (2017) Minimally invasive approaches to adrenal tumors: an up-to-date summary including patient position and port placement of laparoscopic, retroperitoneoscopic, robot-assisted, and single-site adrenalectomy. Curr Opin Urol 27:56–61
doi: 10.1097/MOU.0000000000000339 pubmed: 27533502
Autorino R, Bove P, De Sio M, Miano R, Micali S, Cindolo L, Greco F, Nicholas J, Fiori C, Bianchi G, Kim FJ, Porpiglia F (2016) Open versus laparoscopic adrenalectomy for adrenocortical carcinoma: a meta-analysis of surgical and oncological outcomes. Ann Surg Oncol 23:1195–1202
doi: 10.1245/s10434-015-4900-x pubmed: 26480850
Hu X, Yang W-X, Shao Y-X, Dou W-C, Xiong S-C, Li X (2020) Minimally invasive versus open adrenalectomy in patients with adrenocortical carcinoma: a meta-analysis. Ann Surg Oncol 27:3858–3869
doi: 10.1245/s10434-020-08454-1 pubmed: 32277316
Gokceimam M, Akbulut S, Erten O, Kahramangil B, Kim YS, Li P, Berber E (2021) An intra-operative video comparison of laparoscopic versus robotic transabdominal lateral adrenalectomy. Int J Med Robot Comput Assist Surg 17:e2203
doi: 10.1002/rcs.2203
Gokceimam M, Kahramangil B, Akbulut S, Erten O, Berber E (2021) Robotic posterior retroperitoneal adrenalectomy: patient selection and long-term outcomes. Ann Surg Oncol 28:7497–7505
doi: 10.1245/s10434-021-10088-w pubmed: 33987759
Delozier OM, Stiles ZE, Deschner BW, Drake JA, Deneve JL, Glazer ES, Tsao MW, Yakoub D, Dickson PV (2021) Implications of conversion during attempted minimally invasive adrenalectomy for adrenocortical carcinoma. Ann Surg Oncol 28:492–501
doi: 10.1245/s10434-020-08824-9 pubmed: 32656720
Skertich NJ, Tierney JF, Chivukula SV, Babazadeh NT, Hertl M, Poirier J, Keutgen XM (2020) Risk factors associated with positive resection margins in patients with adrenocortical carcinoma. Am J Surg 220:932–937
doi: 10.1016/j.amjsurg.2020.02.043 pubmed: 32111342
Dickson PV, Kim L, Yen TWF, Yang A, Grubbs EG, Patel D, Solorzano CC (2018) Adjuvant and neoadjuvant therapy, treatment for advanced disease, and genetic considerations for adrenocortical carcinoma: an update from the SSO endocrine and head and neck disease site working group. Ann Surg Oncol 25:3453–3459
doi: 10.1245/s10434-018-6750-9 pubmed: 30218246
DeLong JC, Chakedis JM, Hosseini A, Kelly KJ, Horgan S, Bouvet M (2015) Indocyanine green (ICG) fluorescence-guided laparoscopic adrenalectomy. J Surg Oncol 112:650–653
doi: 10.1002/jso.24057 pubmed: 26420733
Lerchenberger M, Gündogar U, Al Arabi N, Gallwas JKS, Stepp H, Hallfeldt KKJ, Ladurner R (2020) Indocyanine green fluorescence imaging during partial adrenalectomy. Surg Endosc 34:2050–2055
doi: 10.1007/s00464-019-06985-7 pubmed: 31342258
Arora E, Bhandarwar A, Wagh A, Gandhi S, Patel C, Gupta S, Talwar G, Agarwal J, Rathore J, Chatnalkar S (2018) Role of indo-cyanine green (ICG) fluorescence in laparoscopic adrenalectomy: a retrospective review of 55 Cases. Surg Endosc 32:4649–4657
doi: 10.1007/s00464-018-6309-7 pubmed: 29943065
Sebastian M, Rudnicki J (2020) Recommendation for laparoscopic ultrasound guided laparoscopic left lateral transabdominal adrenalectomy. Gland Surg 9:689–694
doi: 10.21037/gs.2020.03.35 pubmed: 32775258 pmcid: 7347810

Auteurs

Joshua Tseng (J)

Division of Minimally Invasive Surgery and Endocrine Surgery, Department of Surgery, Cedars-Sinai Medical Center, 8635 W. 3rd St., Suite 650, Los Angeles, CA, 90048, USA.
Department of Surgery, Kern Medical, Bakersfield, CA, USA.

Timothy Diperi (T)

Division of Minimally Invasive Surgery and Endocrine Surgery, Department of Surgery, Cedars-Sinai Medical Center, 8635 W. 3rd St., Suite 650, Los Angeles, CA, 90048, USA.

Nicholas Gonsalves (N)

Division of Minimally Invasive Surgery and Endocrine Surgery, Department of Surgery, Cedars-Sinai Medical Center, 8635 W. 3rd St., Suite 650, Los Angeles, CA, 90048, USA.

Yufei Chen (Y)

Division of Minimally Invasive Surgery and Endocrine Surgery, Department of Surgery, Cedars-Sinai Medical Center, 8635 W. 3rd St., Suite 650, Los Angeles, CA, 90048, USA.

Anat Ben-Shlomo (A)

Adrenal Program, Pituitary Center, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Daniel Shouhed (D)

Division of Minimally Invasive Surgery and Endocrine Surgery, Department of Surgery, Cedars-Sinai Medical Center, 8635 W. 3rd St., Suite 650, Los Angeles, CA, 90048, USA.

Edward Phillips (E)

Division of Minimally Invasive Surgery and Endocrine Surgery, Department of Surgery, Cedars-Sinai Medical Center, 8635 W. 3rd St., Suite 650, Los Angeles, CA, 90048, USA.

Miguel Burch (M)

Division of Minimally Invasive Surgery and Endocrine Surgery, Department of Surgery, Cedars-Sinai Medical Center, 8635 W. 3rd St., Suite 650, Los Angeles, CA, 90048, USA.

Monica Jain (M)

Division of Minimally Invasive Surgery and Endocrine Surgery, Department of Surgery, Cedars-Sinai Medical Center, 8635 W. 3rd St., Suite 650, Los Angeles, CA, 90048, USA. monica.jain@cshs.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH